This company produces animal-free whey proteins (as an ingredient platform) used to make dairy-style products such as milk, ice cream, cream cheese, and more—primarily by supplying ingredient partners rather than owning the entire consumer brand relationship. It historically used consumer brands to demonstrate market viability but has since reoriented toward B2B ingredient supply.
The technology is precision fermentation: engineered microbes produce bioidentical whey proteins, which are purified into functional ingredients (e.g., its ProFerm line) designed to behave like dairy proteins in formulations. This approach is typical of fermentation-led “real animal protein without the animal” strategies.
Commercial stage: reporting describes a strategic shift away from its consumer brand portfolio toward B2B operations, and ongoing efforts to expand manufacturing capacity (including a reported facility timeline in India).
Availability: earlier consumer products using its proteins were sold in the US and elsewhere, but multiple industry sources describe a pullback/discontinuation wave in animal-free dairy retail even as B2B ingredient work continues.
Timeline and regions: a cited manufacturing plan forecasts initial operations at a Gujarat facility in the second half of 2026 with ramp-up into 2027, which should be treated as company-guided timing subject to execution risk.
